ArticleGlobal health, science and practice2026
The Cost and Intermediate Cost-Effectiveness of a Randomized Control Trial Delivering U=U Messaging to Increase HIV Testing Among South African Men.
Article in Global health, science and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSouth African men have lower HIV testing uptake than their female counterparts, leading to lower antiretroviral treatment (ART) uptake and higher HIV-related mortality. A recent cluster-randomized trial in a high HIV prevalence area in Cape Town showed that relaying the "undetectable equals untransmittable" (U=U) message to South African men increased their HIV testing uptake compared to issuing standard testing invitations. We conducted an economic analysis based on this trial to inform decision-making regarding implementing U=U messaging in routine public-sector HIV care.
methodsWe analyzed the mean cost of the U=U intervention and its intermediate cost-effectiveness over the control arm. Costs were estimated from trial expenditure data in 2020 South African rand (ZAR), converted using March 2020 US$ exchange rates. Shared trial costs were allocated to each arm based on participant volume or days of operation; capital costs, including the creation of the U=U message via human-centered design workshops, were annualized over 8 years. In a second scenario, trial cost was adjusted for potential implementation in routine care.
resultsPeer promoters delivered 504 U=U invitations to test for HIV over 7 intervention days and 544 standard invitations over 5 control days in March 2020. Compared with standard invitations, men who received U=U messaging had 60% increased odds of getting tested for HIV. The average trial cost was $5.40 per U=U message delivered ($2.35 after adjustment for routine implementation), $388.47 per person testing HIV-positive ($168.99 adjusted), and $906.44 per person initiating ART ($394.31 adjusted). Within trial costs, staff, overhead, and research costs were the largest allocations, with each accounting for 20% to 30% of total costs. After routine implementation adjustment, the costs of message creation via human-centered design workshops, personnel (peer promoters, research staff), and supplies were the largest allocations. Cost of U=U messaging per person confirmed HIV-positive and initiating ART was lower than conventional HIV testing messaging and at the lower end of cost ranges of HIV self-test distribution models targeted at men ($62 to $7,936 per person confirmed positive and $117 to $8,198 per person initiating ART) established in previous work.
conclusionDelivering tailored U=U messaging can increase HIV testing and ART uptake among men while saving costs over standard untargeted HIV testing messaging and other HIV self-test distribution models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.